Klaviyo, Inc. Earnings Per Share Disclosure
| Year Ended December 31, | |||||||||||||||||
| 2025 | 2024 | 2023 | |||||||||||||||
Net loss per share attributable to Series A and Series B common stockholders, basic and diluted: | |||||||||||||||||
| Numerator: | |||||||||||||||||
| Net loss | $ | (31,768) | $ | (46,142) | $ | (308,233) | |||||||||||
| Denominator: | |||||||||||||||||
| Weighted-average shares - basic and diluted | 290,896,895 | 266,336,826 | 242,889,272 | ||||||||||||||
Net loss per share attributable to Series A and Series B common stockholders, basic and diluted | $ | (0.11) | $ | (0.17) | $ | (1.27) | |||||||||||
| Year Ended December 31, | |||||||||||||||||
| 2025 | 2024 | 2023 | |||||||||||||||
| Warrants outstanding | 2,410,676 | 3,788,204 | 5,165,732 | ||||||||||||||
| Investment Option | 15,743,174 | 15,743,174 | 15,743,174 | ||||||||||||||
| RSUs outstanding | 14,550,455 | 17,421,450 | 14,690,417 | ||||||||||||||
| Options outstanding | 2,225,979 | 25,164,415 | 31,734,725 | ||||||||||||||
ESPP | 245,840 | 258,033 | — | ||||||||||||||
| Total | 35,176,124 | 62,375,276 | 67,334,048 | ||||||||||||||
About Earnings Per Share Disclosures
The earnings per share disclosure breaks down the calculation from net income to both basic and diluted EPS, revealing the full impact of a company's capital structure on per-share economics. The reconciliation between basic and diluted share counts exposes how many stock options, RSUs, convertible securities, and warrants are potentially dilutive to existing shareholders.
Key signals: a widening gap between basic and diluted shares indicates growing dilution from equity compensation or convertible instruments. Anti-dilutive securities excluded from the diluted calculation deserve attention — they represent latent dilution that will materialize if the stock price rises. Watch for the effect of share buybacks on per-share metrics: EPS growth driven primarily by repurchases rather than income growth signals weakening fundamentals. Compare year-over-year changes in the diluted share count against equity compensation expense to assess whether management is effectively managing dilution.